HFS
VRTX icon

HL Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

HL Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$454K Sell
2,470
-144
-6% -$26.6K 0.01% 527
2018
Q4 		$433K Sell
2,614
-141
-5% -$24.4K 0.01% 525
2018
Q3 		$531K Sell
2,755
-180
-6% -$32.1K 0.01% 510
2018
Q2 		$499K Buy
2,935
+100
+4% +$15.5K 0.01% 494
2018
Q1 		$462K Sell
2,835
-415
-13% -$67.8K 0.01% 509
2017
Q4 		$487K Buy
3,250
+30
+0.9% +$4.44K 0.01% 429
2017
Q3 		$490K Sell
3,220
-220
-6% -$33.1K 0.01% 491
2017
Q2 		$443K Hold
3,440
– – 0.01% 496
2017
Q1 		$376K Buy
3,440
+405
+13% +$35.7K 0.01% 512
2016
Q4 		$224K Sell
3,035
-40
-1% -$3.25K ﹤0.01% 620
2016
Q3 		$268K Sell
3,075
-150
-5% -$14.2K 0.01% 561
2016
Q2 		$277K Sell
3,225
-175
-5% -$15.1K 0.01% 549
2016
Q1 		$270K Buy
+3,400
New +$308K 0.01% 545

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

HL Financial Services's VRTX Position: Q1 2019 in Review

HL Financial Services reduced its Vertex Pharmaceuticals (VRTX) stake by 5.5% in Q1 2019, selling an estimated $26.6K and leaving 2,470 shares worth $454K. The position accounts for 0.01% of the portfolio, ranked #527.

HL Financial Services first reported a position in VRTX in Q1 2016 and has held it in 13 quarters since. The position peaked at $531K in Q3 2018. 737 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

  • HL Financial Services held 2,470 shares of Vertex Pharmaceuticals worth $454K as of Q1 2019.
  • HL Financial Services sold 144 Vertex Pharmaceuticals shares in Q1 2019, an estimated $26.6K.
  • Vertex Pharmaceuticals made up 0.01% of HL Financial Services's portfolio in Q1 2019, its #527 holding.
  • HL Financial Services first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 13 quarters since.
  • HL Financial Services's Vertex Pharmaceuticals position peaked at $531K in Q3 2018.
  • 737 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on HL Financial Services's 13F filing for Q1 2019, filed 1 May 2019.